Table 2

Percentage of directional and non-directional vesicles before and after ATP treatment for control and IFN-γ-treated WT andGFAP-/-Vim-/-astrocytes and slopes of the lines fitted to the vesicle mobility data
Genotype Stimulation Control IFN-γ
Mobility Slope (a ± s.e.m.)a Vesicle Slope (a ± s.e.m.)a Vesicle
(%) (%)
WT Spontaneous
Directional 0.633 ± 0.038c (152)b 8.0 0.575 ± 0.020c (426) 20.3
Non-directional 0.262 ± 0.006 (1748) 92.0 0.219 ± 0.005 (1674) 79.7
ATP
Directional 0.483 ± 0.056c (49) 5.2 0.597 ± 0.059c (62) 5.9
Non-directional 0.266 ± 0.009 (901) 94.8 0.231 ± 0.007 (988) 94.1
GFAP-/-Vim-/- Spontaneous
Directional 0.581 ± 0.068c (75) 4.4 0.553 ± 0.030c (92) 5.7
Non-directional 0.324 ± 0.008 (1625) 95.6 0.329 ± 0.009 (1508) 94.3
ATP
Directional 0.616 ± 0.069c (33) 3.9 0.781 ± 0.148c (20) 2.5
Non-directional 0.298 ± 0.010 (817) 96.1 0.279 ± 0.012 (780) 97.5

aThe slope values (a) ± s.e.m were obtained from the linear function fitted to the mobility data in Figure 6.

bValues inside brackets are numbers of vesicles. The slopes of regression lines for mobility data of directional and nondirectional vesicles differed in control and IFN-γ treated WT and GFAP-/-Vim-/- cells under spontaneous conditions and after ATP treatment.

cP <0.001 vs. non-directional mobility.

Vardjan et al.

Vardjan et al. Journal of Neuroinflammation 2012 9:144   doi:10.1186/1742-2094-9-144

Open Data